RHEUMATOID ARTHRITIS: PROBLEMS OF REMISSION AND RESISTANCE TO THERAPY

##plugins.themes.bootstrap3.article.main##

Abstrak:

Аrthritis (RA) is an immuno–inflammatory (autoimmune) rheumatic disease of unknown etiology, characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and a reduction in the life expectancy of patients. Despite the successes achieved in the treatment of RA associated with the development of new drugs and improving the treatment strategy that allows achieving remission in many patients, there are many theoretical and clinical problems concerning both the definition of the concept of "remission", its characteristics and types, and approaches to the optimal tactics of "symptomatic" and "pathogenetic" drug therapy at different stages of the disease, the use of which will allow you to quickly induce remission and maintain it in the long term.

##plugins.themes.bootstrap3.article.details##

##submission.citations##:

Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In the book: Nasonov EL, Nasonova VA, editors. Rheumatology. National leadership. Moscow: GOTAR-Me-dia; 2008. pp. 290-331 [Nasonov EL, Karateev DE,

Balabanova R.M. Rheumatoid arthritis. In: Nasonov E.L., Nasonova V.A., editors. Rheumatology. National leadership. Rheumatology. National leadership]. Moscow: GEOTAR-Media; 2008. pp. 290-331.

Burmester GR., Pope J. New strategies for the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2338-48. doi: 10.1016/S0140-6736(17)31491-5

McInnes I.B., Schett G. Pathogenetic conclusions from the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2328-37. doi: 10.1016/S0140-6736(17)31472-1

Smolen J.S., Bridveld FC, Burmester GR. and others . Treatment of rheumatoid arthritis by target indicator: updating the recommendations of the international task force for 2014. Ann Reum Dis. 2016;75:3-15. doi: 10.1136/annrheumdis-2015-207524

Combe B, Landewe R, Daien CI, etc. Update of EULAR recommendations for 2016 on the treatment of early arthritis. Ann Reum Dis. 2016;76:948-59. doi: 10.1136/annrheumdis- 2016-210602

Stoffer M.A., Shoels M.M., Smolen Yu.S. et al. Evidence of targeted treatment of rheumatoid arthritis: results of systematic updating of literature sources. Ann Reum Dis. 2016;75:16-22. doi: 10.1136/annrheumdis-2015-207526

Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and controversial issues. Scientific and practical expertise. 2013;51(6):609-22 [ Nasonov EL, Karateev DE, Chichasova N.V. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and controversial issues. Scientific and practical rheumatology = The science and practice of rheumatology. 2013;51(6):609-22 (in Russian)]. doi: 10.14412/1995-4484-2013-609-22

Ajeganova S., van Steenbergen H.U., van Nis Ya.A. et al. Long-term remission in rheumatoid arthritis without the use of anti-rheumatic drugs modifying the disease: an increasingly achievable result with a decrease in the symptoms of the disease. Ann Reum Dis. 2016;75(5):867- 73. doi: 10.1136/annrheumdis-2014-207080

Nagy G., van Vollenhoven RF. Stable remission in rheumatoid arthritis without the use of biological drugs, where are we now? Arthritis, 2015;17:181. doi: 10.1186/s13075-015-0707

Schett G., Emery P., Tanaka Yu. and others . Narrowing the biological and traditional DMARD therapy for rheumatoid arthritis: current data and directions for the future. Ann Reum Dis. 2016;75:1428-37. doi: 10.1136/annrheumdis-2016-209201

Felson D.T., Smolen J.S., Wells G. et al. American College of Rheumatology/The European League against Rheumatism gives a preliminary definition of remission in rheumatoid arthritis for clinical trials. Rheumatoid arthritis. 2011;63:573-86. doi: 10.1002/art.30129

Prevu Jr., van Gestel A.M., van Toph M.A. et al. Remission in a prospective study of patients with rheumatoid arthritis. Preliminary remission criteria of the American Rheumatism Association depending on the assessment of the activity of the disease. Br J Rheumatol. 1996;5:111-5. doi: 10.1093/rheumatology/35.11.1101